Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02537145
Other study ID # P9624
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date September 2015
Est. completion date December 2017

Study information

Verified date September 2018
Source TNO
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this pilot study is to determine the feasibility of Do-It-Yourself studies in pregnant women to detect changes in health parameters by assessing compliance and user experiences of participants. Besides, the measured health will be analysed to increase insight in physiological development in pregnant women.


Description:

The study is designed as an open, parallel, do-it-yourself, explorative, two-group study. Subjects are women who are pregnant for approximately 3 months at the start of the study. Subjects will be included between week 12 and 15 of their pregnancy (T=-1). Week 16 is the start of the study (T=0). In the first group obese pregnant women (BMI ≥ 30) will be included; the second group will consist of lean pregnant women (BMI 18,5 - 25).

The women will be requested to assess physiological parameters at regular intervals from three months pregnancy until giving birth (week 40). The assessment after giving birth, until three months after giving birth (total study duration of approximately nine months), is optional.

Health parameters are known to be subject to change in pregnant women; the self-monitoring devices should be able to show these changes. Included subjects will be provided with the do-it-yourself devices, manuals and the study protocol. During the nine-month study, the subjects will use these do-it-yourself devices to self-monitor multiple health parameters in an at-home setting. They will be reminded to perform these tests via SMS. There are two frequency intervals defined (two week interval and eight week interval).


Recruitment information / eligibility

Status Terminated
Enrollment 16
Est. completion date December 2017
Est. primary completion date July 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

1. Pregnant between 12-15 weeks at the start of the study;

2. Healthy as assessed by the Health and Lifestyle questionnaire (P9624 F02);

3. Body mass index:

- BMI 18,5 - 25 for the lean group

- BMI = 30 for the obese group;

4. Able to use self-monitoring devices;

5. Voluntary participation;

6. Having given written informed consent;

7. Willing to comply with study procedures;

8. Willingness to share pseudonymised data on measured health parameters with external parties that provide the measuring devices (including MijnEetmeter, Moves and NRC) for reasons of synchronisation with the study database;

9. Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data by TNO;

10. Have internet access at home;

11. Subjects should own a Smartphone with Bluetooth that runs either a recent version of iOS or Android.

Exclusion Criteria:

1. Use of concomitant medication;

2. Having a history of medical or surgical events that may significantly affect the study outcome, including physical limitations or cardio-vascular events;

3. Having a (history of a) medical condition that might significantly affect the study outcome as judged by the principal investigator and health and life style questionnaire. This includes diabetes type 1 or 2, gastrointestinal dysfunction, diseases related to inflammation, or a psychiatric disorder;

4. Hypertension: systolic blood pressure >160 mmHg, diastolic blood pressure >90 mmHg;

5. Having a pacemaker;

6. Previous pregnancy with medical issues (e.g. pre-eclampsia);

7. Reported slimming or medically prescribed diet;

8. Physical, mental or practical limitations in using computerized systems;

9. Alcohol consumption > 14 units (drinks)/week;

10. Smoking;

11. Reported unexplained weight loss or gain of > 2 kg in the three months prior to the pre-study screening / pregnancy;

12. Recent blood donation (<1 month prior to the start of the study);

13. Not willing to give up blood donation during the study;

14. Personnel of TNO and their partner.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Netherlands Spaarne Gasthuis Hoofddorp Noord Holland

Sponsors (2)

Lead Sponsor Collaborator
W.J. Pasman Spaarne Gasthuis

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary compliance (percentage of complete datasets) as a measure of the potential of DIY-monitoring in pregnant women end of study (3 months after giving birth)
Primary Capability of and burden for participants of the use of DIY tools as assessed by a questionnaire on user-experience with do-it-yourself devices in an at-home setting end of study (3 months after giving birth)
Secondary fasting blood glucose as measured using a do-it-yourself glucose meter after an overnight fast at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 of pregnancy; optionally after delivery in w42, 44, 46, 48, 50, 52
Secondary body weight as measured by a smart-scale at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 of pregnancy; optionally after delivery in w42, 44, 46, 48, 50, 52
Secondary physical activity (calories burned, minutes of physical activity, number of steps) participants continuously wear the activity tracker during the day for the whole week in each of the above mentioned measurement-weeks at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 of pregnancy; optionally after delivery in w42, 44, 46, 48, 50, 52
Secondary blood pressure (diastolic, systolic, heart rate) as measured with a do-it-yourself blood pressure meter at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 of pregnancy; optionally after delivery in w42, 44, 46, 48, 50, 52
Secondary GPS location measured with an app that will be installed on the Smartphone of the participant at enrollment in the study measured continuously during the entire study
Secondary Cholesterol (total cholesterol, HDL, LDL, triglycerides, cholesterol/HDL-ratio) measured using a do-it-yourself cholesterol meter at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally after delivery in w52
Secondary oral glucose tolerance test (glucose, insulin, c-peptide) in week 16 the test will be done in a clinical setting; the other tests will be done at home by the participants baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally after delivery in w52
Secondary fecal and salivary microbiota composition using do-it-yourself sample collection kits (at home by participants; samples will be send to the lab) at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally also in w18, 27 and 36, and after delivery in w44, 48 and 52
Secondary dried blood spots for HbA1c, fatty acids and blood biomarkers do-it-yourself using finger-prick and blood spot collection cards that can be send to the lab. at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally after delivery in w52
Secondary cortisol in hair measured by taking a hair sample that is send to the lab at the end of the study (3 months after delivery; week 52)
Secondary food intake as measured by a web-application in each measurement week, participants will register their food intake on two week days and one weekend day at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally after delivery in w52
Secondary cognition using online cognition tests (on a study portal) at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally after delivery in w52
Secondary Groninger Sleep Scale online; can be accessed via the study portal at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally after delivery in w52
Secondary Vita16 - vitality questionnaire online; can be accessed via the study portal at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally after delivery in w52
Secondary visual analogue scales for general health online; can be accessed via the study portal at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally after delivery in w52
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2